Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care

Topics covered in Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care include: Epidemiology, clinical features, presentation, pathophysiology, and disease progression, patient population identification among healthcare professionals of ...

Topics covered in Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care include: Epidemiology, clinical features, presentation, pathophysiology, and disease progression, patient population identification among healthcare professionals of different specialties, diagnostic tests, genetic testing and patient cases.After completing Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care, you will be able to: • Describe the pathophysiology of AATD and how it impacts treatment of the disorder • Assess the clinical significance of AATD laboratory results and apply them to patient cases • Describe the clinical presentation of patients with A1ATD and, given a patient case, formulate a treatment plan • Recall barriers to care for AATD and its clinical management in current practiceTarget Audiences: Pulmonologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in pulmonology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with AATD.

---

Write the first review

Resource tags